In the first installment of this CME Outfitters Snack series, expert faculty will guide learners through an overview of challenges and recent developments in immunotherapy, as well as guideline recommendations on their implementation in practice. Faculty will also detail strategies designed to increase implementation of best practices in genetic and biomarker testing for cancer immunotherapy.
0.5 Hours
03/31/2023
Kurt A. Schalper
Dr. Schalper trained as cell/molecular biologist and surgical pathologist. His professional experience includes clinical molecular diagnostics and development of cancer biomarkers.
Kurt A. Schalper
Dr. Schalper trained as cell/molecular biologist and surgical pathologist. His professional experience includes clinical molecular diagnostics and development of cancer biomarkers. His laboratory focuses on understanding dominant immune evasion pathways in human solid tumors and deciphering the structural/functional determinants of the tumor immune microenvironment in lung cancer. Dr. Schalper is also the Director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center where he leads the standardized analysis of biomarkers in clinical trials using advanced cell/tissue analysis platforms.
Banu Arun
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center.
Banu Arun
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. Dr. Arun has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777, and PARP inhibitors for metastatic breast cancer and celecoxib, atorvastatin, dasatinib, and Tamoxifen Gel in short-term breast cancer prevention trials. Her research also includes outreach and education, as well as cascade genetic testing of family members.
Given her national and international expertise, she has served on several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee ASCO Prevention Education Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee and member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well as the NCCN Breast Hereditary Genetics Guideline Committee, member of the ASCO Germline Genetic Testing Guideline Panel, and member of the National Cancer Institute (NCI) Cancer Prevention Steering Committee. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including the Journal of Clinical Oncology, Cancer, British Medical Journal, Cancer Prevention and Epidemiology, amongst others. She has more than 200 peer-reviewed publications and received research grants from the NCI, DoD, Susan Komen Foundation, and CPRIT.
She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Award 2021.
In the second installment of this CME Outfitters Snack series, expert faculty will discuss strategies for providing high-quality genetic counseling and services for underserved patients with cancer, including leveraging health technology (e.g. telehealth), utilizing a collaborative/interprofessional approach to genetic counseling, and implementing a workable process for patient identification and triage.
0.5 Hours
03/31/2023
Yevgeniya Ioffe
Dr. Ioffe is a gynecologic oncologist in Southern California.
Yevgeniya Ioffe
Dr. Ioffe is a gynecologic oncologist in Southern California. She completed her training in gynecologic oncology at Washington University/Barnes-Jewish Hospital in St. Louis. Her practice focus has included improving care of women afflicted with gynecologic malignancies in the underserved San Bernardino and Riverside counties.
Her academic interest has focused on establishing a fellowship training program in gynecologic oncology in those underserved counties.
Her research interests include: impact of genetic and molecular alterations on treatment and outcome of ovarian cancer and improving genetic testing rates in gynecologic oncology patients.
Banu Arun
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center.
Banu Arun
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. Dr. Arun has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777, and PARP inhibitors for metastatic breast cancer and celecoxib, atorvastatin, dasatinib, and Tamoxifen Gel in short-term breast cancer prevention trials. Her research also includes outreach and education, as well as cascade genetic testing of family members.
Given her national and international expertise, she has served on several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee ASCO Prevention Education Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee and member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well as the NCCN Breast Hereditary Genetics Guideline Committee, member of the ASCO Germline Genetic Testing Guideline Panel, and member of the National Cancer Institute (NCI) Cancer Prevention Steering Committee. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including the Journal of Clinical Oncology, Cancer, British Medical Journal, Cancer Prevention and Epidemiology, amongst others. She has more than 200 peer-reviewed publications and received research grants from the NCI, DoD, Susan Komen Foundation, and CPRIT.
She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Award 2021.
In the third installment of this CME Outfitters Snack series, expert faculty will discuss the role of predictive biomarkers in guiding clinical decision-making, practical guidance for testing requirements and recommendations, and shared decision-making. Faculty will also present illustrative examples of utilizing testing to guide therapy.
0.5 Hours
03/31/2023
Robert L. Coleman
Dr. Coleman is the immediate Past-President of the International Gynecologic Cancer Society (IGCS) and was recently inducted into MJH Life Sciences 2020 class of “Giants in Cancer Care.”
Robert L. Coleman
Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. Prior to joining the M.D. Anderson faculty in 2004, he served as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center in Dallas. At M.D. Anderson, Dr. Coleman was a Professor and served as the Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as their Chief Scientific Officer and currently serves as Chief Medical Officer for Sarah Cannon Research Institute (SCRI), a joint venture research organization between USOR and SCRI.
Dr. Coleman has authored or coauthored over 700 scientific publications, including over 410 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. In 2019, he received the 2019 APGO-CREOG award for Excellence in Teaching. He is a co-Director for GOG-Partners and serves on the Board of Directors for GOG-Foundation, Inc. He is the immediate Past-President of the International Gynecologic Cancer Society (IGCS) and was recently inducted into MJH Life Sciences 2020 class of “Giants in Cancer Care.”
Banu Arun
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center.
Banu Arun
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. Dr. Arun has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777, and PARP inhibitors for metastatic breast cancer and celecoxib, atorvastatin, dasatinib, and Tamoxifen Gel in short-term breast cancer prevention trials. Her research also includes outreach and education, as well as cascade genetic testing of family members.
Given her national and international expertise, she has served on several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee ASCO Prevention Education Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee and member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well as the NCCN Breast Hereditary Genetics Guideline Committee, member of the ASCO Germline Genetic Testing Guideline Panel, and member of the National Cancer Institute (NCI) Cancer Prevention Steering Committee. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including the Journal of Clinical Oncology, Cancer, British Medical Journal, Cancer Prevention and Epidemiology, amongst others. She has more than 200 peer-reviewed publications and received research grants from the NCI, DoD, Susan Komen Foundation, and CPRIT.
She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Award 2021.
During this 30-minute CMEO Snack, Drs. Wechsler and Dua will identify best practices and current guidelines for the clinical evaluation and differential diagnosis of EGPA. Using a case presentation to frame the discussion, faculty will explain the differential diagnosis of EGPA as well as how to integrate diagnostic methods and interpret results.
0.5
03/27/2023
Anisha B. Dua, MD, MPH
Anisha B. Dua MD, MPH is an Associate Professor of Medicine in the Division of Rheumatology, Rheumatology Fellowship Program Director, and Director of the Northwestern Vasculitis Center at Northwestern University Feinberg School of Medicine.
Anisha B. Dua, MD, MPH
Anisha B. Dua MD, MPH is an Associate Professor of Medicine in the Division of Rheumatology, Rheumatology Fellowship Program Director, and Director of the Northwestern Vasculitis Center at Northwestern University Feinberg School of Medicine.
Dr. Dua’s interests are in rheumatology education and vasculitis. She completed her Rheumatology fellowship at Rush University as well as fellowships in Medical Education at The University of Chicago and Integrative Medicine at Northwestern.
Dr. Dua currently leads a multidisciplinary team in the clinical management of vasculitis patients. She assisted in the development of the American College of Rheumatology (ACR) Guideline for the Treatment and Management of Vasculitis, is on the Board of Directors for the Vasculitis Foundation, and a member of the Scientific Advisory Council for the Rheumatology Research Foundation. She is the chair of the e-learning Subcommittee and co-chair of the Workforce Solutions Committee, Virtual Training Programs for the ACR. She has served in leadership capacities both locally and nationally through the American College of Rheumatology, the Vasculitis Foundation, and the ACGME in the areas of education as well as vasculitis. You can follow her on twitter @anisha_dua
Michael E. Wechsler
Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health (NJH) in Denver, Director of the NJH/Cohen Family Asthma Institute, and Associate Vice President for Innovation and Industry Relations at NJH.
Michael E. Wechsler
Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health (NJH) in Denver, Director of the NJH/Cohen Family Asthma Institute, and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary and critical care medicine, Professor Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. He has published more than 270 peer-reviewed manuscripts relating to asthma, EGPA, and eosinophilic lung diseases. He was a member of the Steering Committee and site Principal Investigator (PI) of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicenter asthma clinical trials consortium, and currently serves as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation and the Association of American Physicians, he has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society, and the International Eosinophil Society. He is currently Associate Editor of the journal Chest and has served as Associate Editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.<br.
Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and an MD degree from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.</br.
In part two of this REMS CME Outfitters Snack series, host/moderator Dr. Steven Gabardi is joined by Dr. Michael Wu to share strategies for counseling patients of reproductive potential about the risks of pregnancy while taking mycophenolate.
0.50 Hours
10/21/2022
Michael Wu
Michael Wu, MD, RhMSUS, is a rheumatologist and Assistant Professor at Baylor College of Medicine in Houston, Texas.
Michael Wu
Michael Wu, MD, RhMSUS, is a rheumatologist and Assistant Professor at Baylor College of Medicine in Houston, Texas. He has a particular interest in musculoskeletal ultrasound and is an educator in both the Rheumatology Fellowship and Internal Medicine Residency at Baylor. Dr. Wu completed his Internal Medicine training at Northwestern University in Chicago and his Rheumatology training at Johns Hopkins University in Baltimore. He is happy to be back in his home state of Texas treating the wide range of rheumatologic diseases seen in his field.
Steven Gabardi
Steven Gabardi, PharmD, BCPS, FAST, FCCP, is a clinical specialist in organ transplant with the Department of Transplant Surgery at Brigham and Women's Hospital in Boston, MA.
Steven Gabardi
Steven Gabardi, PharmD, BCPS, FAST, FCCP, is a clinical specialist in organ transplant with the Department of Transplant Surgery at Brigham and Women’s Hospital in Boston, MA. He is also an Assistant Professor of Medicine at Harvard Medical School, where he became the first PharmD to receive an academic appointment. Dr. Gabardi earned his PharmD at Butler University?s College of Pharmacy and Health Sciences in Indianapolis, IN in 1999 and subsequently completed his residency in pharmacy practice at Tufts Medical Center in Boston, MA in 2000. After completing his residency, he was hired as a co-funded faculty member at Northeastern University’s Bouvé College of Health Sciences. His clinical practice site was at the Brigham and Women’s Hospital Division of Renal Transplant working in both the inpatient and outpatient settings.
Board-certified as a Pharmacotherapy Specialist and a Fellow of both the American Society of Transplantation and American College of Clinical Pharmacy, Dr. Gabardi has published in a multitude of textbooks and peer-reviewed journals. He has been invited to speak at local, national, and international conferences on many different transplant-related topics. Dr. Gabardi became the first transplant pharmacist to be named an Associate Editor for both the American Journal of Transplantation and Transplantation. He is also an editorial board member for several other peer-reviewed journals.
In part one of this CME Outfitters Snack series, Dr. Miae Kim joins host/moderator Dr. Steven Gabardi to discuss how mycophenolate works in the body, the potential for first trimester pregnancy loss, and the types of congenital malformations that can occur if the mycophenolate REMS is not followed.
0.50 Hours
10/21/2022
Miae Kim
Miae Kim, PharmD, MS, BCPS, received a master's degree in Clinical Pharmacy from Seoul National University in South Korea, then moved to the U.S. where she graduated Summa Cum Laude with high distinction from the University of Minnesota with a PharmD.
Miae Kim
Miae Kim, PharmD, MS, BCPS, received a master’s degree in Clinical Pharmacy from Seoul National University in South Korea, then moved to the U.S. where she graduated Summa Cum Laude with high distinction from the University of Minnesota with a PharmD. She completed her PGY-1 pharmacy practice training at Beth Israel Deaconess Medical Center, and did a PGY-2 training in solid organ transplant at Brigham and Women?s Hospital in Boston. Dr. Kim joined the Center for Advanced Heart Disease at Brigham and Women’s Hospital as a heart transplant/MCS pharmacy specialist in 2013, working in both the inpatient and outpatient settings. She attained board certification as a Pharmacotherapy Specialist in 2013. Dr. Kim’s current interests include cardiac transplant complications, antibody-mediated rejection, and cardiac allograft vasculopathy, and she has published in multiple peer-reviewed journals and textbooks and presented at local, national, and international transplant conferences.
Steven Gabardi
Steven Gabardi, PharmD, BCPS, FAST, FCCP, is a clinical specialist in organ transplant with the Department of Transplant Surgery at Brigham and Women's Hospital in Boston, MA.
Steven Gabardi
Steven Gabardi, PharmD, BCPS, FAST, FCCP, is a clinical specialist in organ transplant with the Department of Transplant Surgery at Brigham and Women’s Hospital in Boston, MA. He is also an Assistant Professor of Medicine at Harvard Medical School, where he became the first PharmD to receive an academic appointment. Dr. Gabardi earned his PharmD at Butler University?s College of Pharmacy and Health Sciences in Indianapolis, IN in 1999 and subsequently completed his residency in pharmacy practice at Tufts Medical Center in Boston, MA in 2000. After completing his residency, he was hired as a co-funded faculty member at Northeastern University’s Bouvé College of Health Sciences. His clinical practice site was at the Brigham and Women’s Hospital Division of Renal Transplant working in both the inpatient and outpatient settings.
Board-certified as a Pharmacotherapy Specialist and a Fellow of both the American Society of Transplantation and American College of Clinical Pharmacy, Dr. Gabardi has published in a multitude of textbooks and peer-reviewed journals. He has been invited to speak at local, national, and international conferences on many different transplant-related topics. Dr. Gabardi became the first transplant pharmacist to be named an Associate Editor for both the American Journal of Transplantation and Transplantation. He is also an editorial board member for several other peer-reviewed journals.
Join our newsletter
Stay up to date on new CME Outfitters activities, breaking news, and important developments in medical education.